Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Helped by a technical support level

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2019 | 02:45am EDT
long trade
Live
Entry price : 73.8€ | Target : 76.35€ | Stop-loss : 71.6€ | Potential : 3.46%
Pursuant to the correction that has taken place in recent weeks with respect to the shares in Sanofi, further downside risk now appears limited by close and important technical support levels at 72.57 EUR.
Investors have an opportunity to buy the stock and target the € 76.35.
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 72.57 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI-0.66%105 046
JOHNSON & JOHNSON8.32%368 655
PFIZER-3.96%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832
MERCK AND COMPANY6.23%208 984
ABBVIE-13.16%118 355
ELI LILLY AND COMPANY0.94%113 383
AMGEN-11.59%104 470
ASTRAZENECA3.68%101 072
GLAXOSMITHKLINE6.09%100 298
Autres valeurs du secteur

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2019 36 116 M
EBIT 2019 8 988 M
Net income 2019 5 019 M
Debt 2019 14 487 M
Yield 2019 4,23%
P/E ratio 2019 17,64
P/E ratio 2020 15,43
EV / Sales 2019 3,00x
EV / Sales 2020 2,81x
Capitalization 93 774 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 83,5 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development